In brief, it appears that combinatorial unimolecular therapies, which incorporate GLP‐1 receptor benefits together with the metabolic advantages of other related gastrointestinal tract‐derived hormones, have unmistakeable therapeutic potential for obesity, diabetes and beyond. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.